Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats

Prisciandaro, Luca D.; Geier, Mark S.; Butler, Ross N.; Cummins, Adrian G.; Howarth, Gordon S.

doi:10.4161/cbt.11.7.14896

Cited by 67 publications

(46 citation statements)

References 40 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A possible explanation for these observations requiring additional investigation is that clinical manifestations of diarrhoea are not exclusively the result of mucositis and that, as in the non-oncology population, disruptions in the normal microbial flora may result in disturbed bowel function. Data supporting such a hypothesis have been derived from intervention studies using probiotic factors, which have proven effective in reducing cancer therapy-induced diarrhoea in the preclinical and clinical settings [75,76]. An additional factor affecting the role of the microbiota may be the effect of the tumour on the immune response.…”

Section: Gut Microbiomementioning

confidence: 99%

Emerging evidence on the pathobiology of mucositis

Al‐Dasooqi

Sonis

Bowen

et al. 2013

Support Care Cancer

165

View full text Add to dashboard Cite

Background Considerable progress has been made in our understanding of the biological basis for cancer therapyinduced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely. Methods Panel members reviewed the biomedical literature on mucositis pathobiology published between January 2005 and December 2011.Results Recent research has provided data on the contribution of tissue structure changes, inflammation and microbiome changes to the development of mucositis. Additional research has focused on targeted therapyinduced toxicity, toxicity clustering and the investigation of genetic polymorphisms in toxicity prediction. This review paper summarizes the recent evidence on these aspects of mucositis pathobiology. Conclusion The ultimate goal of mucositis researchers is to identify the most appropriate targets for therapeutic interventions and to be able to predict toxicity risk and personalize interventions to genetically suitable patients. Continuing research efforts are needed to further our understanding of mucositis pathobiology and the pharmacogenomics of toxicity.

show abstract

Section: Gut Microbiomementioning

confidence: 99%

Emerging evidence on the pathobiology of mucositis

Al‐Dasooqi

Sonis

Bowen

et al. 2013

Support Care Cancer

165

View full text Add to dashboard Cite

show abstract

“…In another recent study using Dark Agouti rats, it was shown that Mutaflor could reduce the side effects of chemotherapy. The supernatants of Mutaflor protected intestine of the rats from 5-fluorouracil-induced mucositis [31]. …”

Section: Basic Mechanisms Of Mutaflormentioning

confidence: 99%

<i>Escherichia coli</i> Nissle 1917 (Mutaflor): New Insights into an Old Probiotic Bacterium

Jacobi

Malfertheiner

2011

Dig Dis

View full text Add to dashboard Cite

Probiotic bacteria are live microorganisms which contribute health benefits to their host. The numerous mechanisms of the probiotic-acting microorganisms include the induction of expression of certain cytokines and increasing the secretion of IgA and mucin. They activate lymphocytes and macrophages and inhibit the adhesion and invasion of epithelial cells. Escherichia coli Nissle 1917 (Mutaflor) is one of the most investigated probiotic bacteria. While the number of reports discussing the underlying mechanisms of Mutaflor has increased rapidly in recent years, novel clinical studies are missing. Here we provide an overview of the mechanisms of action and clinical studies related to Mutaflor. While most of the studies had positive outcomes, there are also a few in which Mutaflor did not perform to its expectations.

show abstract

“…36 Moreover, recently, probiotic-derived factors have begun to show promise at preventing mucositis in vivo and in vitro. 35,37 In addition, there are now early indications that antioxidant and anti-inflammatory constituents in plant extracts, such as Iberogast 38 and grape seed extract, 39 and animal-sourced oils, such as Lyprinol 40 and Emu oil, 41 could have utility in preventing mucositis.…”

Section: Treatment Of Mucositismentioning

confidence: 99%

Newly Developed Synbiotics and the Chemotherapy-Damaged Gut

Wang

Bastian

Howarth

2013

J Evid Based Complementary Altern Med

Self Cite

View full text Add to dashboard Cite

Mucositis is a common side-effect of cancer chemotherapy and radiotherapy. Features of mucositis include erythema, ulceration, and inflammation of the gastrointestinal tract accompanied by clinical symptoms of abdominal pain and digestive disturbances. New treatment strategies are required. Experimental evidence is accumulating showing therapeutic promise for new nutraceutical agents including probiotic bacteria, probiotic-derived factors, prebiotics, and plant extracts. However, the targeted development of new combinations of these agents (synbiotics) to combat mucositis remains largely unexplored. The current review addresses the potential for these nutraceutical agents to reduce the severity of chemotherapy-damaged mucositis by strategically aligning their underlying mechanism of action with features of mucositis pathogenesis. The potential for certain plant extracts to act as prebiotics, in combination with probiotics or their derived factors, is further investigated. These unique synbiotic formulations could form the basis of a new naturally sourced adjunctive approach to cancer chemotherapy.

show abstract

Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats

Cited by 67 publications

References 40 publications

Emerging evidence on the pathobiology of mucositis

Emerging evidence on the pathobiology of mucositis

<i>Escherichia coli</i> Nissle 1917 (Mutaflor): New Insights into an Old Probiotic Bacterium

Newly Developed Synbiotics and the Chemotherapy-Damaged Gut

Contact Info

Product

Resources

About